- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Soumya Vishwanath Gives an Overview of the Therapeutic Gaps in Behavioral Health Disorders
Soumya Vishwanath, PharmD, senior manager of formulary strategy at Magellan Rx Management, highlighted the therapeutic gaps that need to be addressed to ensure that patients with behavioral health disorders are well cared for.
Soumya Vishwanath, PharmD, senior manager of formulary strategy at
Magellan Rx Management, highlighted the therapeutic gaps that need to be addressed to ensure that patients with behavioral health disorders are well cared for.
Transcript
What are some of the therapeutic gaps when it comes to addressing behavioral health disorders?
Some therapeutic gaps that we can think of and that come to mind when addressing behavioral health disorders is really recognizing when for a patient pharmacotherapy may or may not be the right choice. There's different types of pharmacotherapy that's used for patients, but sometimes that may not be fully effective or enough for a patient, and that's where the potential for digital therapeutics can come into space and then into play for these patients.
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
